Health
Merck's melanoma vaccine trial shows reduced recurrence or death from skin cancer
TL;DR
- Merck presented its mRNA melanoma vaccine trial data at a European cancer conference this weekend. Results are promising: The vaccine reduces recurrence and death alongside an immunotherapy drug.
Short summary
Our full write-up is on its way. For the complete story, read the original report:
Oct 26, 2026 · Updated 10/28/2026, 6:44:42 PM · Reported with: NPR Health
Sources (1)
NRI Bytes writes its own articles from the reporting below.
NPR Health — Merck's melanoma vaccine trial shows reduced recurrence or death from skin cancerUp next · Health
Wayanad Experts Address Potential El Niño Impacts on Agriculture and Health
Read next →
